Application of Calculated Panel Reactive Antibody Using HLA Frequencies in Koreans.
- Author:
Ji Young JANG
1
;
Yoon Joo KIM
;
Yonggoo KIM
;
Yeon Joon PARK
;
Kyungja HAN
;
Eun Jee OH
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Panel reactive antibody (PRA); Calculated panel reactive antibody (CPRA); Transplantation; HLA antibody; Sensitization; Unacceptable antigen
- MeSH: *Algorithms; HLA Antigens/immunology; HLA-B Antigens/immunology; HLA-DR Antigens/immunology; *Histocompatibility Testing; Humans; Isoantibodies/*blood/immunology; Phenotype; Republic of Korea
- From:Annals of Laboratory Medicine 2012;32(1):66-72
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Introduction of the Luminex panel reactive antibody (PRA)-single antigen (SA) assay has increased the detection rates of unacceptable antigens in sensitized patients; the calculated PRA (CPRA) level represents the percentage of actual organ donors that express 1 or more of these unacceptable antigens. We developed a CPRA calculator based on the HLA frequencies in Koreans to measure sensitization levels in Korean patients. METHODS: To develop the calculator, we obtained the HLA-A, HLA-B, and HLA-DR phenotypes of 1,622 Koreans, and compared these with previously reported frequencies in Koreans. Sera from patients awaiting kidney transplantation were tested for HLA antibodies by Luminex PRA-screen, PRA-identification (ID), and PRA-SA assays. The measured %PRA from the PRA-screen (N=55) and PRA-ID (N=71) were compared to the %CPRA for the unacceptable antigens obtained from PRA-SA. RESULTS: Phenotype frequencies used for the CPRA calculator agreed with previously reported data. The concordance rates among the 3 PRA methods for the detection of class I and class II antibodies were 76.1-81.8% (kappa, 0.519-0.636) and 72.7-83.6% (0.463-0.650), respectively. For the detection of broadly sensitized sera (>50% or >80%), the concordance rates were over 80%. In sera with 80-100% CPRA, 91.7% and 94.4% of the samples had concordant results (80-100% PRA) in the PRA-screen and PRA-ID assay, respectively. CONCLUSIONS: Although further clinical studies are required to confirm the benefits of CPRA values, adoption of CPRA analysis based on HLA frequencies in Koreans may be useful for sensitization measurements and organ-allocation algorithms.
